SCHEMBL4431085

SCHEMBL4431085

CCOC(=O)C(C)(C)Oc1cc(O)cc2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 9/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HSD17B10 Q99714 1/20 0.46
PPARA Q07869 3/20 0.45
TSHR P16473 2/20 0.45
ABCB11 O95342 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
HTR2A P28223 1/20 0.45
PMP22 Q01453 1/20 0.45
PPARG P37231 2/20 0.43
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
NQO2 P16083 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4424052 0.82 PPARA (0.51) FBP1PPARATSHRABCB11CYP1A2
SCHEMBL4421092 0.81 FBP1 (0.44) FBP1ALDH1A1KDM4EHSD17B10PPARA
SCHEMBL5102873 0.77 FBP1 (0.49) FBP1ALDH1A1KDM4EHSD17B10PPARA
SCHEMBL18898052 0.76 NQO2 (0.38) ALDH1A1KDM4EHSD17B10PPARATSHR
SCHEMBL1550089 0.76 PPARA (0.50) FBP1ALDH1A1PPARATSHRABCB11
SCHEMBL15113871 0.76 NQO2 (0.40) ALDH1A1KDM4EHSD17B10TSHRNQO2
SCHEMBL4111678 0.74 FBP1 (0.58) FBP1PPARATSHRABCB11CYP1A2
SCHEMBL1549946 0.74 PPARA (0.48) FBP1ALDH1A1PPARATSHRABCB11
SCHEMBL1549824 0.73 FBP1 (0.58) FBP1ALDH1A1PPARATSHRABCB11
SCHEMBL4681650 0.73 FBP1 (0.54) FBP1ALDH1A1KDM4EHSD17B10PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495001-B2 Benzannelated derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2009-02-24 US disclosed
EP-1682507-A1 BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2006-07-26 EP disclosed
WO-2005049572-A1 BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-02 WO disclosed
US-20050096336-A1 Benzannelated derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096336-A1 Benzannelated derivatives, their manufacture and use as pharmaceutical agents PPARD, PPARA, PPARG FBP1 1172/4885ALDH1A1 714/4885KDM4E 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.